Literature DB >> 12899557

No improvement in the overall survival of 194 patients with chondrosarcoma in Finland in 1971-1990.

Mirva Söderström1, Tauno O Ekfors, Tom O Böhling, Lyly H I Teppo, Eero I Vuorio, Hannu T Aro.   

Abstract

We describe the clinicopathologic profile and survival of 306 patients with chondrosarcoma reported to the Finnish Cancer Registry in 1971-1990. 218 cases were available for reevaluation. Owing to their various clinicopathologic characteristics, we excluded the histologic variants of chondrosarcoma. Therefore, the final study population included 194 patients. The minimum follow-up was 9 years. The study population included 69 grade 1 tumors, 114 grade 2 tumors, and 11 grade 3 tumors. The commonest tumor sites were the chest, pelvis and femur. A local recurrence developed in 25% of the patients and metastatic lesions in 18%. The patients were treated in 31 hospitals (in 22 hospitals during the 1970s and in 26 in the 1980s), and the number of patients biopsied before the referral remained about the same from the 1970s (15%) to the 1980s (18%). The 5-and 10-year disease-specific survival rates were 70% and 57%, respectively. Multivariate analysis showed that the most important independent predictors of shortened survival were high histologic grade, age 50 years or older, and a diagnosis in the 1980s, as compared to the 1970s. Most findings accorded with reports from specialist treatment centers, but to our surprise, the survival rate declined among patients diagnosed in the 1980s versus the 1970s. The failure to improve patient survival is probably due to treatment of the patients in 31 hospitals rather than in a few centers dealing with treatment of cancer.

Entities:  

Mesh:

Year:  2003        PMID: 12899557     DOI: 10.1080/00016470310014292

Source DB:  PubMed          Journal:  Acta Orthop Scand        ISSN: 0001-6470


  22 in total

1.  Anti-miRNA Oligonucleotide Therapy for Chondrosarcoma.

Authors:  Xiaojuan Sun; Yupeng Chen; Hongchuan Yu; Jason T Machan; Ashna Alladin; Jose Ramirez; Ross Taliano; Jesse Hart; Qian Chen; Richard M Terek
Journal:  Mol Cancer Ther       Date:  2019-07-24       Impact factor: 6.261

2.  Risk factors for metastasis at presentation with conventional chondrosarcoma: a population-based study.

Authors:  Kehan Song; Xiao Shi; Xin Liang; Hongli Wang; Fei Zou; Feizhou Lu; Xiaosheng Ma; Jianyuan Jiang
Journal:  Int Orthop       Date:  2018-04-21       Impact factor: 3.075

Review 3.  [Cartilage tumours of the bone. Diagnosis and therapy].

Authors:  A Streitbuerger; J Hardes; C Gebert; H Ahrens; W Winkelmann; G Gosheger
Journal:  Orthopade       Date:  2006-08       Impact factor: 1.087

4.  Grade I chondrosarcoma of bone: the Münster experience.

Authors:  Arne Streitbürger; Helmut Ahrens; Maurice Balke; Horst Buerger; Winfried Winkelmann; Georg Gosheger; Jendrik Hardes
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-15       Impact factor: 4.553

5.  CXCR4-targeted therapy inhibits VEGF expression and chondrosarcoma angiogenesis and metastasis.

Authors:  Xiaojuan Sun; Cherie Charbonneau; Lei Wei; Wentian Yang; Qian Chen; Richard M Terek
Journal:  Mol Cancer Ther       Date:  2013-05-17       Impact factor: 6.261

Review 6.  Aberrant DNA methylations in chondrosarcoma.

Authors:  Pei Liu; Jacson K Shen; Jianzhong Xu; Carol A Trahan; Francis J Hornicek; Zhenfeng Duan
Journal:  Epigenomics       Date:  2016-09-30       Impact factor: 4.778

7.  Differentiating high-grade from low-grade chondrosarcoma with MR imaging.

Authors:  Hye Jin Yoo; Sung Hwan Hong; Ja-Young Choi; Kyung Chul Moon; Han-Soo Kim; Jung-Ah Choi; Heung Sik Kang
Journal:  Eur Radiol       Date:  2009-12       Impact factor: 5.315

8.  Estimated cause-specific survival continues to improve over time in patients with chondrosarcoma.

Authors:  Kyle R Duchman; Charles F Lynch; Joseph A Buckwalter; Benjamin J Miller
Journal:  Clin Orthop Relat Res       Date:  2014-04-05       Impact factor: 4.176

9.  CXCR4/SDF1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression.

Authors:  Xiaojuan Sun; Lei Wei; Qian Chen; Richard M Terek
Journal:  Mol Cancer       Date:  2010-01-26       Impact factor: 27.401

10.  Diacerein retards cell growth of chondrosarcoma cells at the G2/M cell cycle checkpoint via cyclin B1/CDK1 and CDK2 downregulation.

Authors:  Birgit Lohberger; Andreas Leithner; Nicole Stuendl; Heike Kaltenegger; Werner Kullich; Bibiane Steinecker-Frohnwieser
Journal:  BMC Cancer       Date:  2015-11-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.